Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148495 | 0.82 | HTR6 (1.00) | HTR6MEN1MAPTKMT2A | |
| SCHEMBL3156652 | 0.82 | HTR6 (1.00) | HTR6 | |
| SCHEMBL5434318 | 0.81 | HTR6 (0.54) | HTR6KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL3145307 | 0.76 | HTR6 (1.00) | HTR6MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3152741 | 0.74 | HTR6 (0.81) | HTR6MEN1MAPTKMT2A | |
| SCHEMBL337312 | 0.74 | HTR6 (0.70) | HTR6 | |
| SCHEMBL3154159 | 0.74 | HTR6 (0.73) | HTR6MEN1MAPTKMT2A | |
| SCHEMBL1576075 | 0.73 | HTR6 (0.61) | HTR6 | |
| SCHEMBL3155797 | 0.72 | HTR6 (0.80) | HTR6 | |
| SCHEMBL5470054 | 0.72 | HTR6 (0.74) | HTR6MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648445-B1 | INDOL-5-YL SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | ESTEVE LABOR DR (ES) | 2009-06-03 | — | — | EP | claimed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| CN-1832740-A | Indol-5 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | ESTEVE LABOR DR (ES) | 2006-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | HTR6, NPY5R, NPY2R | HTR6 1/4885KDM4E 3598/4885MEN1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.